B Paul Morgan Selected Research

Peptides (Polypeptides)

6/2010	Targeting neural-restrictive silencer factor sensitizes tumor cells to antibody-based cancer immunotherapy in vitro via multiple mechanisms.
4/2009	Identification of the high affinity binding site in the Streptococcus intermedius toxin intermedilysin for its membrane receptor, the human complement regulator CD59.
7/2008	Modulation of CD59 expression by restrictive silencer factor-derived peptides in cancer immunotherapy for neuroblastoma.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

B Paul Morgan Research Topics

Disease

32	Inflammation (Inflammations) 01/2024 - 09/2003
18	Alzheimer Disease (Alzheimer's Disease) 03/2024 - 03/2009
16	Infections 02/2024 - 01/2002
13	Macular Degeneration (Age-Related Maculopathy) 01/2020 - 02/2007
12	Multiple Sclerosis 01/2024 - 01/2002
12	Neoplasms (Cancer) 01/2022 - 03/2004
10	Demyelinating Diseases (Demyelinating Disease) 01/2024 - 01/2002
10	Myasthenia Gravis 01/2022 - 09/2007
7	Atypical Hemolytic Uremic Syndrome 01/2020 - 01/2007
7	Hemolysis 12/2018 - 12/2003
6	Wounds and Injuries (Trauma) 12/2023 - 06/2011
5	Dementia (Dementias) 03/2024 - 03/2009
5	COVID-19 02/2024 - 11/2020
5	Neurodegenerative Diseases (Neurodegenerative Disease) 01/2024 - 02/2002
5	Peritonitis 12/2023 - 07/2009
5	Neuroinflammatory Diseases 01/2023 - 05/2006
5	Neuromyelitis Optica (Devic's Disease) 01/2022 - 06/2017
4	Experimental Autoimmune Encephalomyelitis (Encephalomyelitis, Autoimmune Experimental) 01/2018 - 01/2002
4	Membranoproliferative Glomerulonephritis (Membranoproliferative Glomerulonephritis, Type II) 05/2014 - 01/2009
3	Schizophrenia (Dementia Praecox) 01/2024 - 01/2020
3	Atherosclerosis 09/2022 - 02/2010
3	Rheumatoid Arthritis 01/2022 - 04/2015
3	Central Nervous System Diseases (CNS Diseases) 12/2021 - 05/2014
3	Disease Progression 01/2021 - 01/2017
3	Psychotic Disorders (Schizoaffective Disorder) 01/2021 - 01/2019
3	Paroxysmal Hemoglobinuria (Paroxysmal Nocturnal Hemoglobinuria) 01/2020 - 12/2014
3	Traumatic Brain Injuries (Traumatic Brain Injury) 11/2015 - 01/2009
3	Proteinuria 02/2004 - 12/2002
2	Kidney Diseases (Kidney Disease) 12/2023 - 03/2013
2	Hemolytic-Uremic Syndrome 11/2023 - 07/2012
2	Acute Kidney Injury (Acute Renal Failure) 11/2023 - 07/2012
2	Guillain-Barre Syndrome 10/2023 - 09/2008
2	CD59 Deficiency 10/2023 - 12/2006
2	Arthritis (Polyarthritis) 01/2022 - 10/2002
2	Sepsis (Septicemia) 12/2021 - 01/2021
2	Renal Insufficiency (Renal Failure) 11/2021 - 12/2002
2	Cognitive Dysfunction 01/2020 - 01/2019
2	Skin Diseases (Skin Disease) 01/2020 - 01/2018
2	Systemic Lupus Erythematosus (Libman-Sacks Disease) 01/2020 - 01/2020
2	Brain Injuries (Brain Injury) 01/2020 - 02/2010
2	Epilepsy (Aura) 08/2018 - 01/2018
2	Leprosy (Hansen's Disease) 01/2016 - 05/2015
2	Meningitis 08/2015 - 03/2013
2	Pneumococcal Meningitis (Streptococcus pneumoniae Meningitis) 08/2015 - 10/2011
2	Human Influenza (Influenza) 01/2013 - 05/2007
2	Communicable Diseases (Infectious Diseases) 11/2012 - 12/2003
2	Lymphoma (Lymphomas) 06/2012 - 02/2003
2	Peritoneal Fibrosis 05/2012 - 07/2009
2	Choroidal Neovascularization 10/2010 - 02/2007
2	Experimental Autoimmune Myasthenia Gravis (Autoimmune Experimental Myasthenia Gravis) 01/2008 - 12/2006

Drug/Important Bio-Agent (IBA)

116	Complement System Proteins (Complement)IBA 03/2024 - 01/2002
20	Complement Membrane Attack Complex (Membrane Attack Complex)IBA 01/2023 - 01/2002
18	Proteins (Proteins, Gene)FDA Link 01/2020 - 03/2003
17	Biomarkers (Surrogate Marker)IBA 02/2024 - 01/2017
13	Complement Factor H (Factor H)IBA 01/2020 - 10/2005
10	AntibodiesIBA 01/2023 - 01/2002
6	Complement Inactivating AgentsIBA 01/2022 - 02/2002
6	Monoclonal AntibodiesIBA 01/2022 - 02/2003
6	Complement Factor B (Factor B)IBA 01/2019 - 01/2007
5	Amyloid (Amyloid Fibrils)IBA 03/2024 - 03/2009
5	Complement C3b (C3bi)IBA 02/2024 - 01/2012
5	Complement C5 (Complement 5)IBA 01/2023 - 10/2011
5	AutoantibodiesIBA 01/2022 - 02/2004
5	Cholinergic ReceptorsIBA 01/2022 - 09/2007
4	Complement Receptors (Complement Receptor)IBA 01/2023 - 10/2002
4	Immunoglobulin G (IgG)IBA 01/2023 - 02/2004
4	CytokinesIBA 01/2021 - 12/2003
4	CD55 Antigens (Decay Accelerating Factor)IBA 09/2005 - 02/2004
3	AnaphylatoxinsIBA 12/2023 - 01/2002
3	ZymosanIBA 12/2023 - 07/2009
3	ApolipoproteinsIBA 01/2023 - 02/2010
3	Anaphylatoxin C5a ReceptorIBA 01/2023 - 10/2011
3	Complement C3 (C3 Complement)IBA 01/2022 - 10/2011
3	AntigensIBA 01/2020 - 05/2009
3	anticomplementIBA 11/2015 - 10/2002
3	Complement C3-C5 Convertases (C3 Convertase)IBA 05/2014 - 01/2011
3	Peptides (Polypeptides)IBA 06/2010 - 07/2008
2	VaccinesIBA 02/2024 - 01/2022
2	Complement C1q (C1q Complement)IBA 01/2023 - 02/2005
2	Apolipoproteins E (ApoE)IBA 01/2023 - 10/2011
2	Fibrinogen (Factor I)FDA Link 01/2023 - 07/2009
2	CholesterolIBA 09/2022 - 01/2019
2	Messenger RNA (mRNA)IBA 01/2022 - 03/2004
2	Antigen-Antibody Complex (Immune Complex)IBA 11/2021 - 09/2003
2	Retinaldehyde (Retinal)IBA 12/2020 - 09/2010
2	eculizumab FDA Link 01/2020 - 10/2019
2	Complement C4 (Complement Component 4)IBA 01/2020 - 01/2009
2	Blood Proteins (Serum Proteins)IBA 01/2020 - 11/2019
2	C-Reactive ProteinIBA 01/2019 - 11/2008
2	ClusterinIBA 01/2017 - 05/2014
2	ParaffinIBA 01/2016 - 03/2004
2	InflammasomesIBA 08/2013 - 07/2013
2	VenomsIBA 07/2012 - 07/2004
2	Transcription Factors (Transcription Factor)IBA 06/2010 - 05/2010
2	muskIBA 07/2008 - 01/2008

Therapy/Procedure

22	Therapeutics 03/2024 - 09/2003
4	Peritoneal Dialysis 12/2023 - 07/2009
4	Immunotherapy 12/2011 - 07/2008
3	Drug Therapy (Chemotherapy) 01/2024 - 02/2006
2	Lasers (Laser) 10/2010 - 02/2007